Economic evaluation of alendronate in the treatment of women with postmenopausal osteoporosis. An analysis on the basis of the Fracture Intervention Trial I;Die wirtschaftlichkelt von alendronat in der behandlung der postmenopausalen osteoporose. Eine analyse auf der grundlage des Fracture Intervention Trial I

Gesundheitsokonomie und Qualitatsmanagement

Volumn 5, Issue 4, 2000, Pages 99-106

  Szucs, T D ^a   Hauselmann, H J ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Alendronate; Cost effectiveness analysis; Costs; Osteoporosis

Indexed keywords

ALENDRONIC ACID;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; FEMALE; FRACTURE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS;

EID: 0033815738     PISSN: 14322625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. A convenient approximation of life expectancy - The DEALE. I. Validation of the method
2. A convenient approximation of life expectancy - The DEALE. II. Use in medical decision-making
3. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
4. Design of the Fracture Intervention Trial
5. Epidemiologie der Osteoporose
6. The economic cost of hip fractures in community-dwelling older adults: A prospective study
7. Prognostic indicators and early home rehabilitation in elderly patients with hip fractures
8. Vitamin D and calcium to prevent hip fractures in elderly women
9. Hip fractures in the elderly: A worldwide projection
10. Kosten-Effektivitats-Analyse von Rocaltrol versus Kalzium in der Behandlung postmenopausalet Osteoporose bei uber 65jahrigen Patienten
11. Influence of treatment factors on the outcome after hip fractures
12. Treatment with alendronate prevents fractures in women at highest risk: Results from the Fracture Intervention Trial
13. Epidemiologie der Osteoporose
14. Postmenopausal estrogens in prevention of osteoporosis: Benefit virtually without risk of cardiovascular of effects are considered
15. Mortality after hip fractures
16. Cost-effectiveness of fracture prevention in established osteoporosis
17. The socioeconomic burden of fractures: Today and in the 21st century
18. Health-related quality of life measurement for evaluation research and policy analysis
19. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups
20. Hip fracture mortality relation to age, treatment, preoperative illness, time of surgery and complications
21. How attractive does a new technology have to be to warrant adoption?
22. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group
23. Long term effect of estrogen replacement therapy on bone mass as measured by dual photon absorptiometry
24. Incidence and direct medical costs of hospitalizations due to osteoporotic fractures in Switzerland
25. Treatment of post-menopausal osteoporosis with transdermal estrogen
26. Clinical outcomes and treatment of hip fractures
27. Survival and ambulation following hip fracture
28. Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose response study
29. Letalitat nach Frakturen des koxalen Femurendes im fortgeschrittenen Alter
30. Die okonomische Bedeutung der Osteoporose in Deutschland
31. Correcting calcium nutritional deficiency prevents spine fractures in elderly women J Bone Miner Res
32. A prospective study on socioeconomic aspects of fracture of the proximal femur
33. Current therapies and future directions in osteoporosis management
34. For the Panel on Cost-Effectiveness in Health and Medicine. Recommendations on reporting cost-effectiveness analyses
35. Clinical and health economic benefit of calcium and vitamin D supplementation in the prevention of osteoporotic fractures
36. Wirtschaftlichkeitsuntersuchungen von medizinischen Therapien
37. Was ist medizinische Okonomie?
38. Five-Hundred Life-Saving interventions and Their Cost-Effectiveness
39. Treatment of post-menopausal osteoporosis with calcitriol or calcium
40. The economics of osteoporosis and its prevention
41. Measurement of health state utilities for economic appraisal
42. Cost-effectiveness of hormone replacement therapy after the menopause
43. Intermittent cyclical etidrorate treatment of postmenopausal osteoporosis
44. Cost-effectiveness of hormone replacement therapy at the menopause
45. Rate of mortality for elederly patients after fracture of the hip in the 1980's
46. The cost of hip fractures